Addario Lung Cancer Medical Institute (ALCMI)

We accelerate investigator-led clinical trials. We pioneer solutions. We inspire hope. Get to know how we can help you with your research, and let's cure lung cancer together! #lungcancer #cancer #oncology

Exciting news from Cofactor Genomics! They have just announced the validation and launch of OncoPrism?-NSCLC, an RNA-based diagnostic tool designed to predict patient responses to immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC). This breakthrough follows the recent Medicare coverage approval for their OncoPrism-HNSCC test, expanding the potential benefits of precision medicine. “OncoPrism-NSCLC dramatically expands the number of patients who can benefit from OncoPrism testing, as NSCLC patients are the largest patient population being treated with ICI," said Dr. Jarret Glasscock, CEO of Cofactor Genomics. "This launch is another important step in achieving Cofactor’s goal of bringing precision medicine to all cancer patients.” Check out the press release on BioSpace here. #lungcancer #oncology #nsclc https://lnkd.in/gnehB67D

At ALCMI, one of the pillars of our research efforts is to uncover the mystery of why younger people are contracting lung cancer. It's an urgent issue. Recently, our consortium partner City of Hope wrote an article about a rising trend in lung cancer among nonsmoking Asian women in their 40s and 50s. It’s a story that’s both heartbreaking and inspiring, shedding light on the urgent need for improved screening and early detection. City of Hope thoracic surgeon Dr. Jae Kim has been researching this phenomenon for years. He notes that two-thirds of these cancers in Asian women display the EGFR mutation, likely influenced by genetic and environmental factors such as air pollution and secondhand smoke. Dr. Kim emphasizes the importance of early detection, which is unfortunately not widely available in the U.S. for nonsmokers. Read the full article here. #lungcancer #efgr #oncology https://lnkd.in/gfTERjCk

An exciting update from UVA Cancer Center! They recently became the first in Virginia to offer lung cancer patients tarlatamab, a new immunotherapy drug approved in May. This drug is set to supercharge the immune system to fight small-cell lung cancer when combined with chemotherapy. Dr. Ryan G., a thoracic medical oncologist at UVA Health, shared insights on this breakthrough, emphasizing the center's robust clinical trial program. "Some of these trials are early phase, developing brand-new drugs, while others are later-phase trials that have the potential to change the standard of care and get an FDA approval," he said. Dive into the full story on UVA Today here. #lungcancer #immunotherapy #tarlatamab https://lnkd.in/ebQ2T3fV

Wow, interesting research that takes a new angle on lung cancer treatment! Researchers at the National University of Singapore, led by Assistant Professor Minh Le , are repurposing nano-sized particles from red blood cells to deliver antisense oligonucleotide (ASO) molecules directly to lung cancer cells. This approach not only targets and suppresses cancer progression but also addresses drug resistance, a major challenge in treating non-small cell lung cancer. You can dive into the full story on ScienceDaily. #lungcancer #medicalinnovation #nsclc https://lnkd.in/detvwjtk

With cold and flu season upon us, the?American Cancer Society?has released an article about the intersection of lung cancer and flu season. Dr. Charu Aggarwal shared some crucial advice for lung cancer patients during this time. Dr. Aggarwal emphasized that lung cancer patients are at a higher risk for respiratory illnesses like the flu due to their compromised immune systems. The doctor advised patients to take preventive measures such as getting vaccinated, practicing good hygiene, and avoiding crowded places. It's a must-read for anyone looking to understand how to better protect themselves or loved ones during the flu season. You can find the full article here. #lungcancer #fluseason https://lnkd.in/gpFxMyrY

Our good friend Dr. Mark Awad at Memorial Sloan Kettering Cancer Center (MSK) recently highlighted some exciting updates on how lung cancer treatments are evolving. For early-stage NSCLC (stage 1, 2, or 3), MSK now uses minimally invasive surgeries like video-assisted thoracic surgery (VATS) and robotic-assisted surgery, resulting in less pain and faster recovery. For advanced stage 4 cancers, a variety of new treatments, including targeted therapies and immunotherapies, are extending lives and improving quality of life. A standout moment was the discussion on MSK's comprehensive genetic testing, which identifies specific mutations and tailors treatments to individual patients. This personalized approach is making a significant impact on patient outcomes. Well worth your time to check out the article here. #lungcancer #nsclc #medicalinnovation https://lnkd.in/gwPvXVQU

Targeted Oncology has an interesting video about the latest therapies and treatment options for recurrent small cell lung cancer (SCLC). Dr. Ariel Lopez-Chavez discusses the current approach to managing recurrent small cell lung cancer, especially in patients who have progressed after first-line chemotherapy. Check out the video here. #lungcancer #sclc https://lnkd.in/gMYmN_ya

As we observe Lung Cancer Awareness Month this November, it's important to highlight the incredible strides being made in the fight against this devastating disease. Lung cancer continues to be the leading cause of cancer-related deaths worldwide, with over 230,000 new cases diagnosed annually in the United States. Early detection, especially through low-dose CT scans, is improving outcomes, but the advancements in treatment are truly revolutionizing care. Our consortium member Northside Hospital recently put together an article outlining a new era of hope for lung cancer patients, authored by Dr. Ming Chi and Dr. Harpaul Gill. Significant progress has been made, particularly with immunotherapy. For instance, patients with unresectable stage III NSCLC and limited stage SCLC are now benefiting from immunotherapy following chemoradiotherapy, significantly improving survival rates. Targeted therapies like Osimertinib and Alectinib are also making a substantial impact, becoming standard treatments for specific genetic mutations. For metastatic lung cancer, chemo-immunotherapy combinations have revolutionized first-line treatment, offering patients longer and better-quality lives. The introduction of innovative therapies, such as Tarlatamab for SCLC, is providing new hope for patients with aggressive forms of the disease. Check out the full article for more. Exciting times! #lungcancer #immunotherapy #medicaldevelopments https://lnkd.in/g7c4j-SK

Our consortium member, City of Hope, recently put together a great article about the cutting-edge advances that are changing the game for lung cancer patients. The article includes updates on advances in chemotherapy, immunotherapy, and radiation therapy. Dr. Ravi Salgia stressed that all treatments have the same goal regardless of modality. "The goal is to cure," he said. “In the most efficacious way, with the least toxicity. Even metastatic lung cancer has to be cured.” Exciting developments and valuable reading. Check it out here. #lungcancer #medicalbreakthroughs #cityofhope https://lnkd.in/gsndvJZx